Karyopharm Therapeutics Inc.’s recent filing unveils that its President and CEO Paulson Richard A. unloaded Company’s shares for reported $6402.0 on Aug 07. In the deal valued at $1.72 per share,3,722 shares were sold. As a result of this transaction, Paulson Richard A. now holds 802,018 shares worth roughly $ 1.11 million.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Then, Poulton Stuart sold 2,845 shares, generating $4,836 in total proceeds. Upon selling the shares at $1.70, the EVP, Chief Development Officer now owns 156,286 shares.
Before that, Paulson Richard A. sold 3,538 shares. Karyopharm Therapeutics Inc. shares valued at $6,085 were divested by the President and CEO at a price of $1.72 per share. As a result of the transaction, Paulson Richard A. now holds 805,740 shares, worth roughly $1.11 million.
Piper Sandler initiated its Karyopharm Therapeutics Inc. [KPTI] rating to an Overweight in a research note published on Monday, January 19, 2023; the price target was $8. PT values the company’s stock at a premium of 82.75 to its Monday closing price.
Price Performance Review of KPTI
On Monday, Karyopharm Therapeutics Inc. [NASDAQ:KPTI] saw its stock fall -4.17% to $1.38. On the same session, the stock had its day’s lowest price of $1.37, but rose to a high of $1.47. Over the last five days, the stock has lost -12.66%. Karyopharm Therapeutics Inc. shares have fallen nearly -59.41% since the year began. Nevertheless, the stocks have fallen -75.83% over the past one year. While a 52-week high of $6.01 was reached on 04/17/23, a 52-week low of $1.36 was recorded on 08/25/23. SMA at 50 days reached $1.6955, while 200 days put it at $3.0152. A total of 0.83 million shares were traded, compared to the trading of 1.44 million shares in the previous session.
Levels Of Support And Resistance For KPTI Stock
The 24-hour chart illustrates a support level at 1.3433, which if violated will result in even more drops to 1.3067. On the upside, there is a resistance level at 1.4433. A further resistance level may holdings at 1.5067. The Relative Strength Index (RSI) on the 14-day chart is 31.45, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.1838, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 95.05%. Stochastics %K at 8.62% indicates the stock is a buying.
How much short interest is there in Karyopharm Therapeutics Inc.?
A steep rise in short interest was recorded in Karyopharm Therapeutics Inc. stocks on Aug 14, 2023, growing by 0.66 million shares to a total of 14.51 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 13.85 million shares. There was a rise of 4.55%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 12.91% of the overall stock float, the days-to-cover ratio (short ratio) rose to 4.11.
Karyopharm Therapeutics Inc. [KPTI] – Who Are The Largest Shareholders?
In filings from BlackRock Fund Advisors, it is revealed that the company now owns 9,038,183 shares, or roughly 7.93% of the outstanding KPTI shares. In other words, the investor’s shares have risen by 2,057,417 from its previous 13-F filing of 6980766.0. Additionally, The Vanguard Group, Inc. increased 15.61% of its stake after which the total value it holdings stand at $15,107,333, while Avidity Partners Management LP reduced -13.12% of its stake to hold $15.07 million in the firm. At present, Marshall Wace LLP is holding 2,443,997 shares valued at $4.4 million. ExodusPoint Capital Management LP owned 2,382,451 shares of the company at the time of its most recent 13F filing, worth $4.29 million.
According to FactSet, Karyopharm Therapeutics Inc.’s share price will average $6.50 in the next year, based on opinions of analysts polled by the firm. This is up nearly 316.67 percent from its previous closing price of $1.44. Analysts expect Karyopharm Therapeutics Inc. stock to reach the higher price of $10.00, while the lowest price estimate is $4.00. However, 10 analysts have rated KPTI stock as an Overweight in their predictions for 2023.